Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT06630416)

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors: a one-minute explainerNCT066304161 min

Biospecimen Collection trial for Metastatic Bladder Urothelial Carcinoma (NCT06630416). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with metastatic bladder cancer or other locally advanced or metastatic solid tumors, with KMT2D, KDM6A, or MTAP loss-of-function alterations. Disease must progress after two treatment lines, unless approved second-line treatment was unsuitable. Prior pemetrexed excludes entry.

The idea: pemetrexed blocks folate-dependent DNA production. Ten-minute infusions repeat every twenty-one days. Folic acid, vitamin B12, and steroids are required. Scans assess tumor response.

This phase 2 study plans 64 patients. Devalingam Mahalingam leads at Northwestern University; Chicago and Orland Park are the two recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.